Significance of Best Spirometry in the First Year After Bilateral Lung Transplantation: Association With 3-Year Outcomes

Manish R. Mohanka, MD,¹ Rohan Kanade, BA,¹ Heriberto Garcia, ACNP,¹ Luke Mahan, FNP-C,¹ Srinivas Bollineni, MD,¹ Jessica Mullins, MD,¹ John Joerns, MD,¹ Vaidehi Kaza, MD,¹ Fernando Torres, MD,¹ Song Zhang, PhD,² and Amit Banga, MD¹

INTRODUCTION
Monitoring protocols after lung transplantation (LT) include a combination of structural and functional assessments of the allograft. While a wide array of tools including radiologic, nuclear medicine, and bronchoscopy are deployed for structural assessments, the cornerstone of functional assessment continues to be the spirometry procedure. This includes serial assessments in pulmonary function laboratory during clinic visits, as well as self-monitoring at home by patients using a microspirometer. The natural history of lung functions after transplantation is well described, where spirometry tends to typically rise rapidly during the first 6–12 months followed by a plateau phase before the inevitable decline, albeit with significant differences between recipients with single and bilateral LT.¹

Serial spirometry assessments are useful by way of early detection of clinically silent allograft dysfunction which can trigger prompt workup and management. The premise of pursuing a proactive approach in this regard is the potential to delay progression to chronic lung allograft dysfunction (CLAD), the clinical correlate encompassing the diverse histologic forms of chronic rejection which leads to irreversible allograft dysfunction. The role of spirometry in this regard cannot be overemphasized. In fact, previous studies have found an association of nonadherence to home spirometry with early progression to CLAD.² Similarly, the pattern of ventilatory abnormality on office spirometry has been found to be associated with long-term outcomes.³,⁴

While previous studies have highlighted the prognostic significance of different patterns of lung function declines after LT, these data do not facilitate prognostication of

Background. Spirometry is the cornerstone of monitoring allograft function after lung transplantation (LT). We sought to determine the association of variables on best spirometry during the first year after bilateral LT with 3-year posttransplant survival. Methods. We reviewed charts of patients who survived at least 3 months after bilateral LT (n = 157; age ± SD: 54 ± 13 y, male:female = 91:66). Best spirometry was calculated as the average of 2 highest measurements at least 3 weeks apart during the first year. Airway obstruction was defined as forced expiratory volume in 1-second (FEV₁)/forced vital capacity (FVC) ratio <0.7. Survival was compared based on the ventilatory defect and among groups based on the best FEV₁ and FVC measurements (>80%, 60%–80%, and <60% predicted). Primary outcome was 3-year survival. Results. Overall, 3-year survival was 67% (n = 106). Obstructive defect was uncommon (7%) and did not have an association with 3-year survival (72% versus 67%, P = 0.7). Although one-half patients achieved an FVC>80% predicted (49%), 1 in 5 (19%) remained below 60% predicted. Irrespective of the type of ventilatory defect, survival worsened as the best FVC (% predicted) got lower (>80: 80.8%; 60–80: 63.3%; <60: 40%; P < 0.001). On multivariate logistic regression analysis, after adjusting for age, gender, transplant indication, and annual bronchoscopy findings, best FVC (% predicted) during the first year after LT was independently associated with 3-year survival. Conclusions. A significant proportion of bilateral LT patients do not achieve FVC>80% predicted. Although the type of ventilatory defect on best spirometry does not predict survival, failure to achieve FVC>80% predicted during the first year was independently associated with 3-year mortality.

(Transplantation 2020;104: 1712–1719.)
individual patients in an effort to customize management strategies. Specifically, it is not known if the pattern of ventilatory defect or the absolute values on the best spirometry achieved during the first year (also referred to as the baseline spirometry) have an association with subsequent posttransplant outcomes. We hypothesized that a higher level of peak lung functions achieved during the first year would be associated with superior posttransplant survival. We also sought to investigate if the presence or type of ventilatory defect (obstructed versus nonobstructed) on the best spirometry measurements were associated with survival.

MATERIALS AND METHODS

This was a retrospective chart review study of patients who underwent LT at the University of Texas Southwestern Medical Center in Dallas, TX, between January 2012 and December 2015 (n = 255). Institutional review board granted approval for the study with a waiver of patient consent (Institutional Review Board #STU042017-036). Given the significant difference in the best spirometry based upon the procedure type, patients with single LT (n = 42) and those who did not survive to 3 months posttransplant (n = 14) were excluded. The group was split into a testing cohort consisting of patients transplanted between 2012 and 2014 (n = 157; age ± SD: 54 ± 13 y, male:female = 91:66) and validation cohort with patients transplanted during 2015 (n = 42; age±SD: 52 ± 14 y, male:female = 27:15).

Management Protocols

The patients are admitted to the lung transplant service after the transplant surgery. After they stabilize and are transferred out of the intensive care unit, in-house daily spirometry recordings are started. Discharge planning includes teaching sessions with the patient and caregiver regarding the outpatient monitoring and follow-up. All patients are managed using a uniform, protocol-based triple immunosuppressive regimen. This includes tacrolimus as the first choice calcineurin inhibitor with goal level of 10–15 ng/mL range in first year and 5–10 ng/mL beyond the first year. Antimetabolite (azathioprine or mycophenolate mofetil) are used with target WBC count <8000/µL. Prednisone dose is gradually tapered down to maintenance dose of 0.1 mg/kg weight at 1-year post lung transplant.

After discharge, patients are seen in the lung transplant clinic twice weekly for first 4 weeks, followed by every week for 4 weeks, every 2 weeks for next 4 weeks and monthly thereafter till the end of first year. A spirometry is done in the clinic with each visit according to the American Thoracic Society guidelines and typically a patient undergoes ~25 visits with each visit according to the American Thoracic Society guidelines and typically a patient undergoes ~25 visits in the first year. 6 Airway obstruction was defined as the transplant indication, pretransplant comorbidities and course, type of procedure, postoperative course including development of primary graft dysfunction (PGD) as well as the duration of intensive care unit (ICU) and hospital length-of-stay, postdischarge spirometry data and posttransplant survival. While development of PGD was determined based on retrospective review, patient charts were prospectively reviewed for the diagnosis and phenotype of CLAD at 3 year posttransplant. Per International Society for Heart and Lung Transplantation guidelines, the diagnosis of CLAD was based upon 20% or more decline in FEV1, for a duration of at least 3 weeks in the absence of other etiologies to explain the decline.

Outcome Parameters

The primary outcome parameter was all-cause mortality at 3-year posttransplant. Additionally, CLAD-free survival was analyzed as the secondary outcome variable.

STATISTICAL ANALYSIS

The study group was divided into 2 groups based upon the 3-year survival. Pretransplant and posttransplant characteristics were compared among the 2 groups using independent t-test, Mann-Whitney U and chi-square analysis as appropriate. The spirometric variables were compared as both continuous (absolute volume and percent-predicted) and categorical variables (using a priori defined cutoffs of percent predicted volumes on spirometry as follows: >80%, 60%–80%, and <60%). Variables significant on univariate analysis along with age, gender, transplant indication, and lung allocation score at match (to ensure that the associations identified were independent of these variables) were entered as covariates in a multivariate logistic regression model to identify variables with an independent association with 3-year mortality.

Finally, given the independent association of best FVC with posttransplant survival, we also compared the characteristics of patients with different levels of FVC impairment using the ANOVA, Kruskal-Wallis test and chi square test as appropriate. Kaplan-Meier analysis was conducted to compare the survival among patients with different levels of impairment on best spirometry.

Statistical significance was considered at P < 0.05 (2-tailed only). The analysis was done using SPSS statistical software (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.)

RESULTS

A majority of recipients had restrictive lung disease as the transplant indication (60.5%) followed by obstructive diseases (22.3%). Mean lung allocation score at match was 53.5 ± 18.9 with more than a quarter of all patients (n = 40) being hospitalized at the time of transplant and 8 patients (5.1%) were bridged to LT using extracorporeal membrane oxygenation support. At 3-year follow-up, all-cause mortality was 32.5% (n = 51) with a CLAD-free survival of 49% (n = 77).

Spirometry Variables During the First Year

Overall, an obstructive ventilatory defect was uncommon on the best spirometry (7%). Mean best FEV1 and FVC were 2.63 ± 0.9 L (84.6% ± 23.3% predicted) and 3.1
± 1.1 L (78% ± 21% predicted). More patients achieved an FEV₁ of >80% predicted (57.3%) when compared with FVC > 80% predicted (49.7%). Nearly 1 in 5 (19%) patients did not achieve an FVC of 60% predicted while the proportion of patients with predicted FEV₁<60% predicted was 14%. The median time to achieving best FVC after transplant was 255 days (range 17–356 d, Figure 1) although this was not different among the 3 FVC groups (Table 1).

Comparison of patient characteristics among the 3 FVC groups is presented in Table 1. Several characteristics including higher LAS at listing and match, hospitalization at the time of transplant, development of PGD grade 2 or 3 at 72-hours posttransplant (27.8% among FVC ≤80% versus 14.1% FVC>80%; OR: 2.4, 1.1–5.3, \( P = 0.049 \)), need of reintubation, higher duration of ventilator need, ICU, and hospital length-of-stay were all associated with low FVC during the first year. While the 3 groups started out with similar mean BMI during their last pretransplant visit as well as during early posttransplant period, patients with higher FVC had proportionally higher weight gain which was statistically significant during the first 3 months. Interestingly, despite an association between lower FVC and worse mortality, the risk of progression to CLAD at 3-year posttransplant was similar among the FVC groups (Table 1).

### 3-year Survival

Pretransplant and posttransplant characteristics among 3 year survivors and nonsurvivors are compared in Table 2. Several spirometry variables were associated with 3 year survival. While the absolute and %-predicted volumes (both FEV₁ and FVC) on best spirometry were significantly lower among nonsurvivors, the FEV₁/FVC ratio was similar. In other words, the presence of airway obstruction on best spirometry was not associated with 3-year survival. However, among patients without airway obstruction (FEV₁/FVC ratio > 0.7), 3-year survival tended to worsen with increase in the ratio above 0.9 (57%) when compared with those with ratio between 07 and 0.9 (71.7%, \( P = \text{NS} \)). Irrespective of the type of ventilatory defect, 3-year survival worsened significantly as the best FVC (% predicted) achieved got lower (<60: 40%; 60–80: 63.3%; >80: 80.8%; \( P < 0.001 \)). Kaplan-Meier analysis showed early and progressive separation of the survival curves for the 3 FVC categories (see Figure 2). Additionally, a longer median time to achieve best FVC after transplant was associated with a higher 3-year survival. In other words, patients who continued to gain FVC beyond the 6-month posttransplant period had a higher 3-year survival.

On multivariate analysis, after adjusting for age, gender, transplant indication, and LAS at match, best FVC (% predicted) during the first year after LT emerged as the independent predictor of 3-year survival (Table 2).

### DISCUSSION

There is limited data in the literature regarding the role of best spirometry as a predictor of posttransplant survival. Previous studies have focused primarily on the prognostic significance of different patterns of decline in the lung functions.³,⁷,⁸ It has been reported that a concurrent FVC and FEV₁ decline portends a much worse prognosis when compared with FEV₁ decline alone. However, the prognostic significance of the ventilatory patterns or the magnitude of best lung functions after LT has not been as well studied. The current study sought to build on the existing literature on the prognostic significance of pulmonary physiology variables on the post-lung transplant outcomes.

While it is logical to strive for the highest possible lung functions after LT, the eventual best spirometry volumes
### TABLE 1.
Characteristics of patients with different percent predicted forced vital capacity categories

| Variable                                      | Best FVC categories (% predicted); mean with SD or proportion (number of patients) |
|-----------------------------------------------|-----------------------------------------------------------------------------------|
|                                               | <60% (n = 30)                       | 80%–60% (n = 49)                     | >80% (n = 78)                      | \( P \)          |
| Age at transplant (y)                         | 54.3 ± 14.2                         | 55 ± 14.6                            | 55 ± 13.5                         | 0.97             |
| Male gender (%)                               | 53.3                                | 59.2                                 | 59                                 | 0.85             |
| Ethnicity                                     |                                     |                                      |                                    |                  |
| Caucasian (%)                                 | 60                                  | 69.4                                 | 74.4                               |                  |
| African American                              | 13.3                                | 14.3                                 | 15.4                               | 0.14             |
| Hispanic                                      | 16.7                                | 14.3                                 | 7.7                                |                  |
| Others                                        | 10                                  | 2                                    | 2.5                                |                  |
| Transplant indication                         |                                     |                                      |                                    |                  |
| Restrictive (%)                               | 66.7                                | 69.4                                 | 52.6                               |                  |
| Obstructive (%)                               | 20                                  | 14.3                                 | 28.2                               | 0.47             |
| Suppurative                                   | 6.7                                 | 12.2                                 | 14.1                               |                  |
| Vascular                                      | 6.6                                 | 4.1                                  | 5.1                                |                  |
| History of diabetes mellitus (%)              | 30                                  | 30.6                                 | 21.8                               | 0.33             |
| Pretransplant 6-min walk distance >200 m (%)   | 48.3                                | 54.2                                 | 67.5                               | 0.13             |
| Pretransplant course from home (%)            | 53.3                                | 71.4                                 | 84.6                               | 0.003            |
| Pretransplant use of ECMO (%)                 | 10                                  | 4.1                                  | 3.8                                | 0.66             |
| Use of cardiopulmonary bypass during transplant (%) | 60                                  | 51                                   | 43.6                               | 0.29             |
| LAS at listing                                | 52 ± 18.7                           | 48.5 ± 16                            | 44.1 ± 14.1                        | 0.049            |
| LAS at match                                  | 61.4 ± 20.4                         | 54.9 ± 18.5                          | 49.6 ± 17.7                        | 0.012            |
| PGD score at 72 h (%)                         |                                     |                                      |                                    |                  |
| 0                                             | 40                                  | 42.9                                 | 61.5                               |                  |
| 1                                             | 30                                  | 30.6                                 | 24.4                               | 0.23             |
| 2                                             | 16.7                                | 14.3                                 | 10.3                               |                  |
| 3                                             | 13.3                                | 12.2                                 | 3.8                                |                  |
| Duration of intubation (d) \(^a\)            | 6 (1–42)                            | 3 (1–15)                             | 2 (1–13)                           | \(<0.001\)       |
| Need of reintubation                           | 21.4%                               | 4.3%                                 | 2.6%                               | 0.002            |
| Duration of ICU stay (d) \(^a\)              | 11 (4–52)                           | 7 (2–35)                             | 4 (2–48)                           | \(<0.001\)       |
| Duration of hospital stay (d) \(^a\)         | 23.5 (5–72)                         | 16 (7–43)                            | 13 (7–63)                          | \(<0.001\)       |
| Need for admission to IPR (%)                 | 53.3                                | 36.7                                 | 28.2                               | 0.05             |
| Use of steroid pulse during the first mo after transplant (%) | 23.3                                | 14.3                                 | 7.7                                | 0.08             |
| Obstructive ventilatory defect (%)            | 10                                  | 6.1                                  | 6.4                                | 0.14             |
| Body mass index at transplant (kg/m\(^2\))   | 23.4 ± 5.1                          | 24.5 ± 5                             | 24 ± 4.5                           | 0.61             |
| Body mass index at 3 mo posttransplant (kg/m\(^2\)) | 23.2 ± 4.6                         | 24.2 ± 4.9                           | 24.5 ± 4.2                         | 0.39             |
| Body mass index at 12 mo posttransplant (kg/m\(^2\)) | 24.1 ± 5.0 (n = 24) | 27.1 ± 6.0 (n = 45) | 27.1 ± 5.4 (n = 75) | 0.06             |
| Proportional change in weight during first 3 mo after transplant \(^a\) (%) | 2 (−19 to 31) | 3 (−30 to 24) | 5 (−14 to 34) | \(0.004\)       |
| Proportional change in weight during the first y after transplant \(^a\) (%) | 5 (−24 to 39) | 10 (−20 to 47) | 14 (−12 to 59) | 0.06             |
| Median time to best FVC (d)                   | 240.5 (45–350)                      | 255.5 (17–346)                       | 258 (21–356)                       | 0.25             |
| Time to best FVC (%)                          |                                     |                                      |                                    |                  |
| 0–3 mo                                        | 13.8                                | 16.3                                 | 7.7                                |                  |
| 3–6 mo                                        | 20.7                                | 16.3                                 | 17.9                               | 0.7              |
| 6–9 mo                                        | 34.5                                | 26.6                                 | 30.8                               |                  |
| 9–12 mo                                       | 31                                  | 40.8                                 | 43.6                               |                  |
| Transbronchial biopsy A grade (%)             |                                     |                                      |                                    |                  |
| 0                                             | 91.7                                | 69                                   | 76.5                               | 0.09             |
| 1                                             | 8.3                                 | 19                                   | 20.6                               |                  |
| 2                                             | None                                | 12                                   | 2.9                                |                  |
| Transbronchial Biopsy B grade (%)             |                                     |                                      |                                    |                  |
| 0                                             | 100                                 | 85.3                                 | 89.7                               |                  |
| 1                                             | None                                | 9.8                                  | 10.3                               | 0.12             |
| 2                                             | None                                | 4.9                                  | None                               |                  |
| C4d positivity (%)                            | 33.3                                | 7.3                                  | 13.2                               | 0.06             |
| Organizing pneumonia (%)                      | None                                | 4.9                                  | 1.45                               | 0.61             |
| Airway stenosis needing intervention (%)      | None                                | None                                 | 2.9                                | 0.13             |

Continued next page
tend to be highly variable among patients, even if we restrict the analysis to bilateral LT only. In consonance with previous articles, the current study also showed a wide variation in the best spirometry with a significant proportion of patients not even achieving 60% of predicted volumes. The findings from the current study were somewhat unexpected considering that only patients with bilateral LT were included. Apart from Mason et al who somewhat expected considering that only patients with predicted volumes. The findings from the current study were similar, thereby excluding weight gain as the etiology. Previous studies have found pathological findings of diffuse alveolar damage, as strongly associated with poor outcomes and often these pathologies would lead to a restrictive ventilatory defect with a low FVC. It is also possible that low FVC resulting from extraparenchymal disorders such as chest wall restriction, or neuromuscular weakness may limit ability to track changes in FEV1, thereby limiting ability of spirometry to detect changes in FEV1 as a trigger for further evaluation. While we did not record specific indicators of frailty, there were trends indicating poor conditioning at baseline (pretransplant 6-min walk distance), early need of pulse dose corticosteroids and a tumultuous early postoperative course (longer duration of intubation, ICU and hospital length of stay as well as need of admission to the inpatient rehabilitation unit after discharge from the hospital) contributing to the lower peak FVC during the first year (Table 1). Irrespective of the etiology though, the strong, independent and graded association of low FVC with worsening 3-year survival highlights the prognostic significance of this simple to track variable. The cutoffs for best FVC identified in the current study, at the very least, can be useful in prognostication of patients with regard to their risk of 3 year mortality. Interestingly, we found the risk of CLAD at 3-year postlung transplant is similar across the FVC groups despite significantly lower CLAD free-survival. This is contrary to expectation that both rates of CLAD and mortality at 3-years would be higher in the group with the lowest FVC. This highlights the limitations in the sensitivity of spirometry in detecting allograft dysfunction especially among LT recipients with low FVC. In other words, among recipients with low FVC due to variety of reasons, allograft function may progressively deteriorate without getting detected eventually resulting in worse mortality risk. Further research is warranted to better define specific etiologies related to restrictive ventilatory defect which may portend worse posttransplant survival. Additionally, a customized management plan for each patient aimed at achieving a sustained level of FVC weight during the first year after transplantation in the testing cohort. The mean BMI among patients with best FVC > 80% predicted and ≤80% at 3, 6, 9, and 12 months was similar, thereby excluding weight gain as the etiology.

### TABLE 1. (Continued)

| Variable                        | Best FVC categories (% predicted); mean with SD or proportion (number of patients) |
|---------------------------------|-------------------------------------------------------------------------------------|
| Donor-specific antibodies (%)   | <60% (n = 30) 50 | 80%–60% (n = 49) 48.9 | >80% (n = 78) 50.7  |
| 3-y survival (%)                | 40  | 63.3 | 80.8  |
| Cause of death                  | 40  | 63.3 | 80.8  |
| ALAD                            | 4   | 4   | 4   |
| CLAD                            | 8   | 5   | 3   |
| Infection                       | 5   | 3   | 0   |
| Miscellaneous                   | 1   | 6   | 8   |
| CLAD free survival at 3 y       | 30% | 44.9 | 59%  |

aData presented as median with range and comparison between the group was done using the Kruskal Wallis Test.

# Data presented as median with range and comparison between the group was done using the Kruskal Wallis Test.

Airway disorder.

Malignancy (n = 2), chronic liver disease (n = 1), graft vs host disease (n = 1), suicide (n = 1), and unknown (n = 1).

Malignancy (n = 4), suspected drug overdose (n = 2), airway disorder (n = 1), and sudden circulatory death (n = 1).

ALAD, acute lung allograft dysfunction; CLAD, chronic lung allograft dysfunction; ECMO, extracorporeal membrane oxygenation; FVC, forced vital capacity; ICU, intensive care unit; IPR, inpatient rehabilitation unit; LAS, lung allocation score; PGD, primary graft dysfunction; SD, standard deviation.
| Variable | Three-y survival; Mean with SD or proportion (number of patients) | Adjusted odds ratio (95% CI) | P |
|----------|------------------------------------------------------------------|----------------------------|---|
| Age at transplant (y) | Yes (n = 106) 56.5 ± 12.6 | No (n = 51) 51.4 ± 15.8 | 0.047 |
| Body mass index at transplant (kg/m²) | Yes (n = 106) 24.3 ± 4.4 | No (n = 51) 23.5 ± 5.5 | 0.35 |
| Proportional change in weight during first 3 mo after transplant (%) | Yes (n = 106) 3 (−30 to 29) | No (n = 51) 4 (−19 to 34) | 0.47 |
| Proportional change in weight during the first y after transplant (%) | Yes (n = 106) 11 (−24 to 46) | No (n = 51) 10 (−17 to 59) | 0.71 |
| Male gender (%) | Yes (n = 106) 59.4 | No (n = 51) 54.9 | 0.61 |
| Ethnicity | | | |
| Caucasian (%) | Yes (n = 106) 71.7 | No (n = 51) 66.7 | |
| African American (%) | Yes (n = 106) 15.1 | No (n = 51) 13.7 | 0.26 |
| Hispanic (%) | Yes (n = 106) 9.4 | No (n = 51) 15.7 | |
| Others | Yes (n = 106) 3.8 | No (n = 51) 3.9 | |
| Transplant indication | | | |
| Restrictive (%) | Yes (n = 106) 64.2 | No (n = 51) 52.9 | |
| Obstructive | Yes (n = 106) 22.6 | No (n = 51) 21.6 | 0.19 |
| Suppurative | Yes (n = 106) 10.4 | No (n = 51) 15.7 | |
| Vascular | Yes (n = 106) 2.8 | No (n = 51) 9.8 | |
| History of diabetes mellitus (%) | Yes (n = 106) 23.6 | No (n = 51) 31.4 | 0.33 |
| Patients in the hospital at the time of transplant (%) | Yes (n = 106) 23.6 | No (n = 51) 29.4 | 0.44 |
| Pretransplant use of ECMO (%) | Yes (n = 106) 5.7 | No (n = 51) 3.9 | 0.11 |
| Pretransplant need of mechanical ventilation (%) | Yes (n = 106) 10.4 | No (n = 51) 11.8 | 0.79 |
| LAS at listing | | | |
| Yes (n = 106) 47.5 ± 16.7 | No (n = 51) 46 ± 14.1 | 0.57 |
| LAS at match | Yes (n = 106) 53.3 ± 19.3 | No (n = 51) 54.1 ± 18.2 | 0.8 |
| PGD score at 72 h (%) | | | |
| 0 | Yes (n = 106) 53.8 | No (n = 51) 47.1 | |
| 1 | Yes (n = 106) 25.5 | No (n = 51) 31.4 | 0.8 |
| 2 | Yes (n = 106) 13.2 | No (n = 51) 11.7 | |
| 3 | Yes (n = 106) 7.5 | No (n = 51) 9.8 | |
| Duration of intubation (d) | Yes (n = 106) 3 (1–15) | No (n = 51) 3 (1–142) | 0.47 |
| Duration of ICU stay (d) | Yes (n = 106) 6 (2–52) | No (n = 51) 6 (2–30) | 0.38 |
| Duration of hospital stay (d) | Yes (n = 106) 14 (8–65) | No (n = 51) 16 (7–72) | 0.27 |
| FEV₁ (L) | Yes (n = 106) 2.76 ± 0.85 | No (n = 51) 2.35 ± 0.98 | 0.01 |
| FEV₁ (% predicted) | Yes (n = 106) 69.6 ± 21.3 | No (n = 51) 74.3 ± 24.1 | <0.001 |
| FVC (L) | Yes (n = 106) 3.3 ± 1 | No (n = 51) 2.69 ± 1.1 | 0.001 |
| FVC (% predicted) | Yes (n = 106) 83 ± 18.7 | No (n = 51) 67.6 ± 21.9 | <0.001 |
| FEV₁/FVC ratio | Yes (n = 106) 84 ± 8.7 | No (n = 51) 87.4 ± 14.5 | 0.12 |
| Obstructive ventilatory defect | | | |
| >80% | Yes (n = 106) 59.4% | No (n = 51) 29.4% | <0.001 |
| 60%–80% | Yes (n = 106) 29.2% | No (n = 51) 35.3% | 2.85 (1.21–6.69) 0.016 |
| <60% | Yes (n = 106) 11.3% | No (n = 51) 35.3% | 7.92 (2.92–21.47) <0.001 |
| Median time to best FVC (d) | Yes (n = 106) 271 (21–356) | No (n = 51) 201 (17–344) | 0.001 |
| Time to best FVC | | | |
| 0–3 mo | Yes (n = 106) 9.5% | No (n = 51) 15.7% | |
| 3–6 mo | Yes (n = 106) 11.4% | No (n = 51) 31.4% | 0.004 |
| 6–9 mo | Yes (n = 106) 31.4% | No (n = 51) 27.4% | |
| 9–12 mo | Yes (n = 106) 47.7% | No (n = 51) 25.5% | |
| Transbronchial biopsy A grade | | | |
| 0 | Yes (n = 106) 75% | No (n = 51) 81.6% | 0.66 |
| 1 | Yes (n = 106) 19.8% | No (n = 51) 13.1% | |
| 2 | Yes (n = 106) 5.2% | No (n = 51) 5.3% | |
| Transbronchial Biopsy B grade | | | |
| 0 | Yes (n = 106) 89.5% | No (n = 51) 92.1% | 0.66 |
| 1 | Yes (n = 106) 8.4% | No (n = 51) 7.9% | |

Continued next page
variables that can contribute to allograft dysfunction leading to lower best lung functions. There was lack of association with demographic variables which is understandable given the comparisons were done for percent predicted volumes which accounts for the demographic variations. Similarly, lack of association with BMI at baseline is related to infrequent occurrence of obesity among these patients early after LT. In fact, while the absolute BMI at different time-points after transplant was similar among the 3 FVC groups, the proportional increase in median BMI was significantly more among patients with higher FVC perhaps indirectly reflecting better nutritional status and conditioning among these patients. The lack of association with diagnostic group was surprising although there appeared to be a trend favoring higher proportion of patients with obstructive disease in the higher FVC category. This is to be expected given the larger size of the chest cavities among these patients in comparison to restrictive diseases. Patients with lower listing and match LAS as well as those coming from home (in contrast to those in the hospital at the time of transplant) were likely to end up with higher FVC levels. This finding appears to be related to such patients being of higher acuity and severity of illness. Further, the interplay of grade 2–3 PGD, resulting in early and significant allograft dysfunction, complicated by the higher frequency of need for reintubation and longer ICU and hospital length of stay that lead to worse debility can all contribute towards limiting the level of FVC that can be achieved. Nevertheless, the association of PGD with low FVC may not be linear as the difference in the incidence of different PGD grades across the 3 groups did not reach statistical significance (Table 1). This is in consonance with the well-established link between late PGD with CLAD, which is believed to be due to the unmasking of epitopes on the alveolar epithelial lining due to the free radical injury which tends to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.

The current study has some limitations. This was a retrospective chart review study evaluating associations that are vulnerable to interactions from hidden confounders. Such a design does not allow interpretations with regard to causality among the associations which must await further evaluation. While majority patients tend to trigger a premature, profound and sustained alloimmune response. In this regard, it is intriguing that development of grade 2–3 PGD is associated with early and persistent ill-effects on the allograft’s ability to achieve its full potential as assessed on spirometry.
and markedly diverse conditions can impact it. For example, posttransplant debility or weight gain can both lead to lower FVC but can improve with time and effort with little contribution from the pulmonary parenchyma. However, neither of these flaws undermines the prognostic significance of the best FVC achieved during the first year and its utility as a potential target for patients to achieve after bilateral LT.

It is concluded that while a majority of patients with bilateral LT achieve >80% of their predicted lung functions on spirometry, a significant proportion do not. The best FVC achieved during the first year after bilateral LT has a strong and independent association with 3 year mortality. Efforts aimed at maximizing the FVC achieved during the first year may help to improve outcomes.

REFERENCES

1. Mason DP, Rajeswaran J, Li L, et al. Effect of changes in postoperative spirometry on survival after lung transplantation. J Thorac Cardiovasc Surg. 2012;144:197–203.
2. Kugler C, Fuehner T, Dierich M, et al. Effect of adherence to home spirometry on bronchiolitis obliterans and graft survival after lung transplantation. Transplantation. 2009;88:129–134.
3. Belloli EA, Wang X, Murray S, et al. Longitudinal forced vital capacity monitoring as a prognostic adjunct after lung transplantation. Am J Respir Crit Care Med. 2015;192:209–218.
4. Suhling H, Dettmer S, Rademacher J, et al. Spirometric obstructive lung function pattern early after lung transplantation. Transplantation. 2012;93:230–235.
5. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–338.
6. Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment—a consensus report from the pulmonary council of the ISHLT. J Heart Lung Transplant. 2019;38:493–503.
7. Todd JL, Jain R, Pavlisko EN, et al. Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction. Am J Respir Crit Care Med. 2014;189:159–166.
8. Woodrow JP, Shlobin OA, Barnett SD, et al. Comparison of bronchiolitis obliterans syndrome to other forms of chronic lung allograft dysfunction after lung transplantation. J Heart Lung Transplant. 2010;29:1159–1164.
9. Arcasoy SM, Cordova FC. The fall in FVC after lung transplantation. A sentinel event. Am J Respir Crit Care Med. 2015;192:127–128.
10. Eberlein M, Permutt S, Chahla MF, et al. Lung size mismatch in bilateral LT is associated with allograft function and bronchiolitis obliterans syndrome. Chest. 2012;141:451–460.
11. Sato M, Hwang DM, Ohmori-Matsuda K, et al. Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation. J Heart Lung Transplant. 2012;31:354–363.
12. Paraskeva M, McLean C, Ellis S, et al. Acute fibrinoid organizing pneumonia after lung transplantation. Am J Respir Crit Care Med. 2013;187:1360–1368.
13. Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2007;175:507–513.

### TABLE 3.
Sensitivity analysis for the independent association of peak FVC category with 3-y posttransplant survival

| FVC categories (% predicted) | Complete group (n = 157) | Sensitivity analysis conditional upon 1-y survival (n = 143) |
|-----------------------------|-------------------------|-------------------------------------------------|
| >80%                        | Reference               | Reference                                      |
| 60%–80%                     | 2.85 (1.21-6.69)        | 3.31 (1.23-8.91)                               |
| <60%                        | 7.92 (2.92-21.47)       | 6.98 (2.26-21.54)                              |

aP < 0.05.  
bP < 0.01.  
cP < 0.001.  
CI, confidence interval; FVC, forced vital capacity.